What is Human Metabolome Technologies Current Ratio?
Human Metabolome TechnologiesTSE:6090 +0.84%59 Current Ratio is 5.26 as of Dec. 2025, which is at its 10-year median of 5.26. GuruFocus rates TSE:6090 with a GF Score™ of 59/100 and a GF Value™ of 円529.55 (Modestly Overvalued). The stock has 4 warning signs investors should review. Among 213 Medical Diagnostics & Research companies, Human Metabolome Technologies ranks better than 83.57% on this metric.
Human Metabolome Technologies has a current ratio of 5.26. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Human Metabolome Technologies's Current Ratio or its related term are showing as below:
TSE:6090'
s Current Ratio Range Over the Past 10 Years
Min: 3.19 Med: 5.26 Max: 16.91
Current: 4.73
During the past 12 years, Human Metabolome Technologies's highest Current Ratio was 16.91. The lowest was 3.19. And the median was 5.26.
TSE:6090's Current Ratio is ranked better than 83.57% of 213
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.1
vs TSE:6090: 4.73
Human Metabolome Technologies (TSE:6090) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Human Metabolome Technologies Current Ratio Related Terms
Human Metabolome Technologies Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TSE:6090 vs TMO, DHR, IDXX: Current Ratio Comparison
For the Diagnostics & Research subindustry, Human Metabolome Technologies's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Human Metabolome Technologies Current Ratio vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Human Metabolome Technologies's Current Ratio distribution charts can be found below:
* The bar in red indicates where Human Metabolome Technologies's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Human Metabolome Technologies (TSE:6090) has a Current Ratio of 5.26 as of Dec. 2025. This is near median its historical median of 5.26. Over the past decade, Human Metabolome Technologies' Current Ratio has ranged from 3.19 to 16.91. According to the industry distribution chart, Human Metabolome Technologies ranks #35 out of 213 companies in the Medical Diagnostics & Research industry, placing it in the top 16.4%.
Is Human Metabolome Technologies' Current Ratio too high?
Human Metabolome Technologies' current Current Ratio of 5.26 is near median its 10-year median of 5.26. Over the past 10 years, this metric has ranged from a low of 3.19 to a high of 16.91. The Medical Diagnostics & Research industry median Current Ratio is 2.10. Human Metabolome Technologies' value of 5.26 is 150.5% above this industry median. Based on the distribution chart, Human Metabolome Technologies ranks #35 out of 213 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Human Metabolome Technologies has a GF Score™ of 59/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Human Metabolome Technologies' Current Ratio compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Human Metabolome Technologies ranks #35 out of 213 companies for Current Ratio. This places Human Metabolome Technologies in the top 16% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.10. Human Metabolome Technologies' value of 5.26 is 150.5% above this benchmark. Historically, Human Metabolome Technologies' own Current Ratio has ranged from 3.19 to 16.91 over the past decade. While the company's 10-year median is 5.26 vs. the industry median of 2.10, Human Metabolome Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Medical Diagnostics & Research company?
The median Current Ratio among Medical Diagnostics & Research companies is 2.10, based on 213 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Human Metabolome Technologies's current Current Ratio of 5.26 is 150.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Medical Diagnostics & Research industry, the median Current Ratio is 2.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Human Metabolome Technologies's current Current Ratio is 5.26, which is near median its own 10-year median of 5.26. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Human Metabolome Technologies stock overvalued right now?
Based on GuruFocus' analysis, Human Metabolome Technologies (TSE:6090) is currently considered Modestly Overvalued. The stock's GF Value™ is 円529.55, compared to a current price of 円598.00 — trading 12.9% above its estimated fair value. The current Current Ratio is 5.26, which is near median its 10-year median of 5.26 and 150.5% above the Medical Diagnostics & Research industry median of 2.10. Human Metabolome Technologies' overall GF Score™ is 59/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Human Metabolome Technologies (TSE:6090), the current Current Ratio is 5.26 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Human Metabolome Technologies (TSE:6090) Overvalued in 2026?
Based on GuruFocus' analysis, Human Metabolome Technologies stock appears to be overvalued.
The current stock price of 円598.00 is trading 12.9% above its estimated GF Value™ of 円529.55.
GuruFocus considers Human Metabolome Technologies to be Modestly Overvalued.
Key valuation signals for TSE:6090:
Current Ratio: 5.26 (near median its 10-year median of 5.26)
GF Value™: 円529.55 vs. price of 円598.00 (12.9% above fair value)
Industry Position: 150.5% above the Medical Diagnostics & Research median (#35 of 213)
No single metric tells the full story. See the TSE:6090 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Human Metabolome Technologies Business Description
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TSE:6090 has been successfully added to your 
